
Precisis
Informationen zu medikamentenresistenter fokaler Epilepsie und einer minimal-invasiven Behandlungsoption, wenn Medikamente keine ausreichende Anfallskontrolle bieten.
Series B+ ·
Amount not disclosed in a source on record.
Funding history ↓Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | undisclosed | — | fundraisingfox.com |
Similar Health and bio companies
AAlaiko$30M Series A · Jan 2022VVumedi$140M Series B+ · Nov 2026
NNeurosterix$105M Series B+ · Nov 2026
OOSMUNDA$14.99M Series B+ · Nov 2026
BBoston Medical Sciences$34.69M Series B+ · Nov 2026
AAraceli Biosciences$4.5M Seed · Nov 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/precisis (get a free API key).